Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
NTLA Nasdaq
ISIN US45826J1051 SEC CIK 1652130 LEI 5493002T5BCPE5DZC723
Follow Intellia Therapeutics
Weekly email: filings, results
Revenue, last quarter
$7.2M
−48% vs same quarter last year
Net income
−$127.5M
−25.8% vs same quarter last year
EPS, diluted
−$0.91
+1.1% vs same quarter last year
Operating cash flow
−$85.4M
−11.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $67.7M | −$412.7M |
| FY24 | $57.9M | −$519M |
| FY23 | $36.3M | −$481.2M |
| FY22 | $52.1M | −$474.2M |
| FY21 | $33.1M | −$267.9M |
| FY20 | $58M | −$134.2M |
| FY19 | $43.1M | −$474.2M |
| FY18 | $30.4M | −$85.3M |
| FY17 | $26.1M | −$67.5M |
| FY16 | $16.5M | −$31.6M |
| FY15 | - | −$12.4M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −651.7% | −609.9% |
| FY24 | - | −923.1% | −896.8% |
| FY23 | - | −1420.5% | −1326.5% |
| FY22 | - | −879% | −909.8% |
| FY21 | 100% | −810.4% | −810.5% |
| FY20 | 100% | −235.5% | −231.5% |
| FY19 | 100% | −246.8% | −1100.1% |
| FY18 | 100% | −298.6% | −280.4% |
| FY17 | - | −266.3% | −258.6% |
| FY16 | - | −195.2% | −192% |
| FY15 | - | - | - |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$395.9M |
| FY24 | −$354.7M |
| FY23 | −$408.1M |
| FY22 | −$346.8M |
| FY21 | −$237.8M |
| FY20 | −$53.5M |
| FY19 | −$110M |
| FY18 | −$67.6M |
| FY17 | −$75.4M |
| FY16 | $29.9M |
| FY15 | −$4.3M |
| FY14 | - |
- Intellia Therapeutics
- Healthcare median
Show the numbers
| Year | Intellia Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −609.9% | −30.6% |
| FY24 | −896.8% | −47% |
| FY23 | −1326.5% | −58% |
| FY22 | −909.8% | −80.4% |
| FY21 | −810.5% | −71.9% |
| FY20 | −231.5% | −62.2% |
| FY19 | −1100.1% | −46.3% |
| FY18 | −280.4% | −49.6% |
| FY17 | −258.6% | −45.9% |
| FY16 | −192% | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |